SHP389 is an allosteric SHP2 Inhibitor with (SHP2 IC50 - 36 nM). SHP389 modulates MAPK signaling in vivo.SHP389 improved SHP2 bioactive compound and cellular potency in trend with increasing lipophilicity. References: Bagdanoff J, Chen Z, Acker MG, Chen YP, Chan H, Doré M, Firestone B, Fodor M, Fortanet J, Hentemann M, Kato M, Koenig R, LaBonte LR, Liu S, Mohseni M, Ntaganda R, Sarver P, Smith T, Sendzik M, Stams T, Spence S, Towler CS, Wang H, Wang P, Williams SL, LaMarche MJ. Optimization of Fused-Bicyclic Allosteric SHP2 Inhibitors. J Med Chem. 2019 Jan 28. doi: 10.1021/acs.jmedchem.8b01725. [Epub ahead of print] PubMed PMID: 30688462.

纯度：≥98%

CAS：2235394-90-6